title: Effect of morphine on the reduced uteroplacental perfusion model of pre-eclampsia in rats.
abstract: OBJECTIVE
  To investigate the effect of morphine on the reduced uteroplacental perfusion pressure (RUPP) model of pre-eclampsia in rats.
  
  
  METHODS
  The abdominal aorta and ovarian arteries of pregnant rats were isolated and clipped on gestational day 14. The chronic morphine treatment group received naltrexone 5 mg/kg 1h before each dose of morphine. L-nitromonomethylarginine 2 mg/kg was administrated in the same pattern. The control group received saline 10 ml/kg. Systolic blood pressure, blood urea nitrogen (BUN), creatinine, creatinine clearance, urinary protein, urinary nitrite/nitrate excretion, and fetal and placental weights were determined.
  
  
  RESULTS
  Morphine significantly reduced systolic blood pressure, fetal and placental weights, plasma BUN, creatinine and urinary protein in RUPP rats compared with control rats. Urinary nitrite/nitrate excretion and creatinine clearance were significantly increased in response to morphine treatment.
  
  
  CONCLUSIONS
  Morphine reduced blood pressure and improved renal function in the RUPP model of pre-eclampsia, but this was associated with reduced fetal and placental weights.
authors: Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors: P
authors: P
authors: Javadian
authors: B
authors: B
authors: Salmanian
authors: M
authors: M
authors: Javadi-Paydar
authors: A A
authors: AA
authors: Shamshirsaz
authors: S
authors: S
authors: Ejtemaei Mehr
authors: M H
authors: MH
authors: Gharedaghi
authors: A R
authors: AR
authors: Dehpour
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D047109:Fetal Development / Q000187:drug effects; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D009020:Morphine / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000494:pharmacology; D009566:Nitrates / Q000652:urine; D009569:Nitric Oxide / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D009573:Nitrites / Q000652:urine; D021041:Placental Circulation / Q000187:drug effects*; D010929:Placentation / Q000187:drug effects; D011225:Pre-Eclampsia / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley; D017450:Receptors, Opioid, mu / Q000819:agonists* / Q000037:antagonists & inhibitors; D051437:Renal Insufficiency / Q000209:etiology / Q000517:prevention & control; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D004791:Enzyme Inhibitors; D009292:Narcotic Antagonists; D009566:Nitrates; D009573:Nitrites; D017450:Receptors, Opioid, mu; D009569:Nitric Oxide; D009020:Morphine; D019001:Nitric Oxide Synthase